First Report of KPC Variants Conferring Ceftazidime-avibactam Resistance in Colombia: Introducing KPC-197

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 May 3

PMID 38700337

Authors

Elsa De la Cadena

Maria Fernanda Mojica

Laura J Rojas

Betsy E Castro

Juan Carlos Garcia-Betancur

Steven H Marshall

Natalia Restrepo

Nancy Patricia Castro-Caro

Magalis Fonseca-Carrillo

Christian Pallares

Robert A Bonomo

Maria Virginia Villegas

Affiliations

Soon will be listed here.

Abstract

Importance: Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.

Citing Articles

Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible ST11 is related to low mutation rates.

Pariona J, Vasquez-Ponce F, Becerra J, Martins-Goncalves T, Pariona E, Madueno F Microbiol Spectr. 2024; 12(10):e0117324.

PMID: 39190636 PMC: 11448024. DOI: 10.1128/spectrum.01173-24.

References

Antonelli A, Giani T, Di Pilato V, Riccobono E, Perriello G, Mencacci A . KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019; 74(8):2464-2466. DOI: 10.1093/jac/dkz156. View

Rojas L, Weinstock G, De la Cadena E, Diaz L, Rios R, Hanson B . An Analysis of the Epidemic of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Convergence of Two Evolutionary Mechanisms Creates the "Perfect Storm". J Infect Dis. 2017; 217(1):82-92. PMC: 5853647. DOI: 10.1093/infdis/jix524. View

van Duin D, Bonomo R . Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016; 63(2):234-41. PMC: 4928383. DOI: 10.1093/cid/ciw243. View

Poirel L, Nordmann P . Rapidec Carba NP Test for Rapid Detection of Carbapenemase Producers. J Clin Microbiol. 2015; 53(9):3003-8. PMC: 4540946. DOI: 10.1128/JCM.00977-15. View

Shields R, Nguyen M, Press E, Chen L, Kreiswirth B, Clancy C . Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother. 2017; 61(5). PMC: 5404588. DOI: 10.1128/AAC.00079-17. View

Mojica M, De la Cadena E, Garcia-Betancur J, Porras J, Novoa-Caicedo I, Paez-Zamora L . Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of and Pseudomonas aeruginosa in Latin American Hospitals. mSphere. 2023; 8(2):e0065122. PMC: 10117078. DOI: 10.1128/msphere.00651-22. View

Carattoli A, Arcari G, Bibbolino G, Sacco F, Tomolillo D, Di Lella F . Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrob Agents Chemother. 2021; 65(10):e0057421. PMC: 8448114. DOI: 10.1128/AAC.00574-21. View

Gaibani P, Campoli C, Lewis R, Volpe S, Scaltriti E, Giannella M . In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018; 73(6):1525-1529. DOI: 10.1093/jac/dky082. View

Hernandez-Garcia M, Castillo-Polo J, Cordero D, Perez-Viso B, Garcia-Castillo M, Fuente J . Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection. J Clin Microbiol. 2022; 60(3):e0224521. PMC: 8925889. DOI: 10.1128/jcm.02245-21. View

10.

Findlay J, Poirel L, Juhas M, Nordmann P . KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021; 65(9):e0089021. PMC: 8370223. DOI: 10.1128/AAC.00890-21. View

11.

Appel T, Mojica M, De la Cadena E, Pallares C, Radice M, Castaneda-Mendez P . In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries. Antibiotics (Basel). 2020; 9(2). PMC: 7168198. DOI: 10.3390/antibiotics9020062. View

12.

Rada A, Hernandez-Gomez C, Restrepo E, Villegas M . Distribution and molecular characterization of beta-lactamases in Gram-negative bacteria in Colombia, 2001-2016. Biomedica. 2019; 39(s1):199-220. DOI: 10.7705/biomedica.v39i3.4351. View

13.

Munoz-Price L, Poirel L, Bonomo R, Schwaber M, Daikos G, Cormican M . Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013; 13(9):785-96. PMC: 4673667. DOI: 10.1016/S1473-3099(13)70190-7. View

14.

Dulyayangkul P, Douglas E, Lastovka F, Avison M . Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020; 64(10). PMC: 7508580. DOI: 10.1128/AAC.00409-20. View

15.

Saavedra S, Bernal J, Montilla-Escudero E, Arevalo S, Prada D, Valencia M . Complexity of Genomic Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Colombia Urges the Reinforcement of Whole Genome Sequencing-Based Surveillance Programs. Clin Infect Dis. 2021; 73(Suppl_4):S290-S299. PMC: 8634422. DOI: 10.1093/cid/ciab777. View

16.

Ocampo A, Chen L, Cienfuegos A, Roncancio G, Chavda K, Kreiswirth B . A Two-Year Surveillance in Five Colombian Tertiary Care Hospitals Reveals High Frequency of Non-CG258 Clones of Carbapenem-Resistant Klebsiella pneumoniae with Distinct Clinical Characteristics. Antimicrob Agents Chemother. 2015; 60(1):332-42. PMC: 4704171. DOI: 10.1128/AAC.01775-15. View

17.

Garcia J, Nastro M, Cejas D, Santana G, Mancino M, Hidalgo M . Emergence of ceftazidime/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America. Clin Microbiol Infect. 2020; 26(9):1264-1265. DOI: 10.1016/j.cmi.2020.03.013. View

18.

Vasquez-Ponce F, Bispo J, Becerra J, Fontana H, Pariona J, Esposito F . Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant belonging to high-risk clones ST11 and ST16 in South America. Microbiol Spectr. 2023; :e0037423. PMC: 10580961. DOI: 10.1128/spectrum.00374-23. View

19.

Olson R, Assaf R, Brettin T, Conrad N, Cucinell C, Davis J . Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR. Nucleic Acids Res. 2022; 51(D1):D678-D689. PMC: 9825582. DOI: 10.1093/nar/gkac1003. View

20.

Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T . Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics (Basel). 2022; 11(5). PMC: 9137602. DOI: 10.3390/antibiotics11050628. View